|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.26 USD | +0.13% |
|
+0.13% | +77.87% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 06-25 | Major deals involving US drugmakers and biotechs over the past decade | RE |
| Market Cap | 10.08B 8.87B 8.24B 7.57B 14.21B 976B 14.46B 98.49B 38.41B 476B 37.84B 37.02B 1,652B | P/E 2026 * |
-31.1x | P/E 2027 * | -24x |
|---|---|---|---|---|---|
| Enterprise Value | 9.1B 8B 7.44B 6.84B 12.82B 881B 13.05B 88.92B 34.68B 430B 34.17B 33.43B 1,491B | EV / Sales 2026 * |
1,001x | EV / Sales 2027 * | 747x |
| Free-Float |
94.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Apogee Therapeutics, Inc.
| 1 day | +0.13% | ||
| 1 week | +0.13% | ||
| Current month | +1.15% | ||
| 1 month | +1.04% | ||
| 3 months | +52.07% | ||
| 6 months | +91.75% | ||
| Current year | +77.87% |
| 1 week | 134.01 |  | 134.4 |
| 1 month | 132.55 | | 134.4 |
| Current year | 60.35 | | 134.4 |
| 1 year | 34.34 | | 134.4 |
| 3 years | 14.19 | | 134.4 |
| 5 years | 14.19 | | 134.4 |
| 10 years | 14.19 | | 134.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 36 | 31/08/2022 | |
Jane Henderson
DFI | Director of Finance/CFO | 60 | 31/12/2022 |
Tim Piringer
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Fox
BRD | Director/Board Member | 54 | 21/06/2023 |
William Jones
BRD | Director/Board Member | 62 | 31/05/2023 |
| Director/Board Member | 36 | 31/05/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/07/26 | Don | Chief Technology Officer | -8,000 | 0.0143% | ||
| 10/07/26 | Don | Chief Executive Officer | -75,046 | 0.1340% | ||
| 01/07/26 | Fiscal year | Chief Technology Officer | 13,750 | 0.0246% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | +0.13% | +230.85% | +558.14% | 10.08B | |
| +1.40% | -3.13% | -2.90% | +13.29% | 46.35B | |
| +3.13% | +5.34% | +402.93% | +605.08% | 40.13B | |
| +2.14% | +2.95% | +10.83% | +65.45% | 36.33B | |
| +4.43% | -1.51% | +6.73% | -9.17% | 34.6B | |
| +1.23% | -2.05% | +0.56% | +30.76% | 26.77B | |
| +0.29% | -2.75% | - | - | 16.66B | |
| +14.71% | +12.62% | +38.50% | +146.99% | 16.91B | |
| -0.03% | -5.95% | +0.30% | +8.01% | 13.05B | |
| +1.82% | +0.19% | +1.45% | -30.74% | 13.05B | |
| Average | +2.80% | +0.43% | +76.59% | +154.20% | 25.39B | |
| Weighted average by Cap. | +2.71% | +0.22% | +82.93% | +150.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.09M 8M 7.43M 6.83M 12.81M 880M 13.04M 88.82M 34.64M 429M 34.13M 33.39M 1.49B | 12.5M 10.99M 10.21M 9.39M 17.62M 1.21B 17.93M 122M 47.64M 590M 46.93M 45.91M 2.05B |
| Net income | -318M -279M -259M -239M -447M -30.75B -455M -3.1B -1.21B -15B -1.19B -1.17B -52.03B | -416M -366M -340M -313M -587M -40.33B -597M -4.07B -1.59B -19.67B -1.56B -1.53B -68.24B |
| Net Debt | -980M -861M -800M -736M -1.38B -94.86B -1.41B -9.57B -3.73B -46.27B -3.68B -3.6B -161B | -740M -651M -605M -556M -1.04B -71.68B -1.06B -7.23B -2.82B -34.96B -2.78B -2.72B -121B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | US$134.26 | +0.13% | 691,294 |
| 22/07/26 | US$134.08 | -0.09% | 1,411,045 |
| 21/07/26 | US$134.20 | +0.04% | 428,085 |
| 20/07/26 | US$134.15 | +0.11% | 917,537 |
| 17/07/26 | US$134.00 | -0.06% | 1,875,281 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- APGE Stock
Select your edition
All financial news and data tailored to specific country editions
